Interventions to Prevent or Redcue the Severity of Frailty
Transitions between frailty, prefrailty, and nonfrail states occur. If risk factors for the development of frailty can be identified, interventions to preserve or enhance functional capacity can be instituted concurrently with cancer therapy. The at-risk or prefrail patient is the ideal candidate for preventive interventions to maintain or improve physical function during or after cancer therapy.
Evidence suggests that exercise can minimize several physiologic changes associated with aging. In one study, physically active adults were more likely to survive to age 80 years or more and had half the risk of dying with a disability. Another study showed that even in individuals in home-care programs, active patients were less likely to die than those with no or low-intensity physical activity. This relationship was noted even for patients over age 80.
Resistance training in particular is effective in improving strength and increasing muscle mass in older adults. In a systematic review of 62 randomized clinical trials, Latham identified improvements in muscle strength and gait speed. However, improvement in aerobic capacity and balance was inconsistent. Exercise training appears to be effective in elderly populations considered to be frail, such as those in nursing homes.[43,49] For the very old or frail, scheduled daily activity such as walking or housekeeping can help postpone frailty and prolong independence.
Progression to frailty may also be delayed by managing the chronic conditions and geriatric syndromes identified by CGA. In a pilot evaluation of early breast cancer patients over the age of 70, CGA assessment resulted in 17 interventions per patient and was felt to influence oncologic treatment in 4 of 11 patients. Arnoldi et al evaluated a CGA model in 153 patients over age 70 to help identify those eligible for oncologic treatment or supportive care. The CGA identified 30 borderline and 14 frail individuals. Although therapy choices were not dictated by CGA results, a higher percentage of nonfrail subjects received therapy, and frail subjects were significantly more likely to die in 6 months than nonfrail patients.
In a randomized trial, McCorkle et al evaluated a CGA assessment vs usual postsurgical care in cancer patients undergoing surgery. A home-care intervention was planned based on the comprehensive assessment. Postsurgical cancer patients receiving the specialized CGA-based home-care intervention had improved survival compared to the usual care group. The data available about elderly cancer patients suggest that it is important to identify and consider frailty before finalizing diagnosis and therapy plans.
Treatment of Breast Cancer in the Frail Elderly
Diagnosis and Treatment of the Primary Lesion
The benefits of mammographic screening are questionable in the frail elderly, and such imaging should be avoided for women with an estimated survival of less than 5 years. Annual breast examination should suffice for finding breast cancers serious enough to have an impact on the frail elderly woman's survival and quality of life. Nevertheless, mammography is still likely to be performed in many of these patients and will occasionally detect early nonpalpable breast cancers.
If a suspicious lesion is detected mammographically, the physician is then compelled to evaluate the abnormality, and a biopsy is needed. In general, core biopsy is preferred over fine-needle aspiration since core biopsy is superior in establishing whether the breast lesion represents in situ or invasive carcinoma and can also be used for assessment of estrogen and progesterone receptors. For some frail patients, excision of the breast lesion—especially if it is negative for both estrogen and progesterone receptors—may be the best approach. In most frail patients treated with lumpectomy and whose tumors have clear margins, radiation therapy is not likely to be of any survival benefit and can be omitted. For frail women with hormone receptor–positive lesions, primary endocrine therapy with either tamoxifen or an aromatase inhibitor (AI) should be considered.
A wealth of data exist on the use of tamoxifen as primary therapy in older women with breast cancer, including several randomized trials comparing tamoxifen alone to mastectomy or lumpectomy. Such trials have generally shown no significant difference in survival for tamoxifen-treated patients compared to those receiving surgical intervention. About 75% of women treated with tamoxifen alone have a complete or partial response.
In one trial of 100 frail elderly women with breast cancer, 40% of patients had a complete response (median duration: 47 months) and 22% a partial response (median duration: 26 months). Time to disease progression was about 15 months for the remaining patients. After a median follow-up of about 5 years, only 11% of patients required surgery for local progression. Other trials using tamoxifen alone show similar results. For women with an estimated survival of 5 years, surgery is superior for local control of the primary lesion, but for the frail patient, endocrine therapy alone is likely to provide local control for the duration of the patient's life.
Aromatase inhibitors have been shown to be superior to tamoxifen in randomized trials in the adjuvant, neoadjuvant, and metastatic setting.[54-57] AIs are not associated with an increased risk of endometrial cancer or thromboembolism. Frail elders without hysterectomy are unlikely to have the annual pelvic examinations needed for monitoring tamoxifen therapy, and the lower physical activity levels in frail elders may increase their risk of tamoxifen-related thromboembolism. AIs are associated with a modestly increased risk of fractures compared to tamoxifen, but this risk can be overcome with the use of oral bisphosphonates. For frail patients who progress on initial endocrine therapy, other hormonal agents can be used for disease control. For the frail elder who is not amenable to surgery and who presents with hormone receptor–negative breast cancer, chemotherapy or local radiation therapy might be considered for those with symptoms or rapid tumor growth.
Systemic Adjuvant Therapy
Healthy elders with hormone receptor–positive cancer derive major benefits from tamoxifen therapy, with annual risk reductions in relapse, breast cancer mortality, and new contralateral breast cancer of 30% to 50%.[58,59] The recent meta-analysis conducted by the Early Breast Cancer Trialists' Collaborative Group shows that the majority of breast cancer relapses in hormone receptor–positive patients occurs after 5 years, irrespective of tamoxifen use.
Frail elders with hormone receptor–positive breast cancers are only likely to benefit from adjuvant endocrine therapy with either tamoxifen or AIs if they have an extremely high risk of relapse within a 5-year period. Estimates of the benefits of treatment can be made using the Web-based program Adjuvant! Online (www.adjuvantonline.com). This program factors in the US census–derived mortality data by age, and one can add an estimate of comorbidity to the program to factor in the effect of coexisting illness on treatment benefit. An example of how this can help in treatment selection is shown in Table 5. This example shows that endocrine treatment is likely to be of minimal to no value in improving survival in most frail elders, whose survival would likely be even worse without treatment than that of the patient with poor health used in this example. Moreover, the effectiveness of more intensive chemotherapy (for example, the dose-dense therapy described in this table) when added to endocrine therapy is likely overestimated in this program.
Frail elders with hormone receptor–negative breast cancer and with an expected survival of less than 5 years are not candidates for current adjuvant chemotherapy regimens, even if they have extensive nodal involvement.
The authors have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.
1. Yancik R: Population aging and cancer: A cross-national concern. Cancer J 11:437-441, 2005.
2. Yancik R: Cancer burden in the aged: An epidemiologic and demographic overview. Cancer80:1273-1283, 1997.
3. Ries LAG, Melbert D, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2004. Bethesda, MD; National Cancer Insitiute. Based on November 2006 SEER data submission, posted to the SEER website, 2007. Available at http://seer.cancer.gov/csr/1975_2004/. Accessed Nov 11, 2007.
4. National Center for Health Statistics, United States Census Bureau. Vital Statistics of the United States. Hyattsville, MD; National Center for Health Statistics, 2001.
5. Yancik R, Ries LG, Yates JW: Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival. Cancer 63:976-981, 1989.
6. Kimmick GG., Hughes KS, Muss HB: Breast cancer in older women, in Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the Breast, pp 1323-1338. Philadelphia, Lippincott Williams & Wilkins; 2004.
7. Ferrucci L, Guralnik JM, Studenski S, et al: Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: A consensus report. J Am Geriatr Soc 52:625-634, 2004.
8. Ferrucci L, Guralnik JM, Cavazzini C, et al: The frailty syndrome: A critical issue in geriatric oncology. Crit Rev Oncol Hematol 46:127-137, 2003.
9. Cohen HJ: In search of the underlying mechanisms of frailty. J Gerontol A Biol Sci Med Sci 55:M706-M708, 2000.
10. Fried LP, Tangen CM, Walston J, et al: Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146-M156, 2001.
11. Fried LP, Kronmal RA, Newman AB, et al: Risk factors for 5-year mortality in older adults: The Cardiovascular Health Study. JAMA 279:585-592, 1998.
12. Fried LP, Ferrucci L, Darer J, et al: Untangling the concepts of disability, frailty, and comorbidity: Implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 59:255-263, 2004.
13. Balducci L: Geriatric oncology: Challenges for the new century. Eur J Cancer 36:1741-1754, 2000.
14. Fried LP, Walston J: Frailiy and failure to thrive, in Hazzard WR, Blass JP, Ettinger WH, et al (eds): Principles of Geriatric Medicine and Geontology pp 1387-1402. New York, McGraw-Hill, 1999.
15. Rodin MB, Mohile SG: A practical approach to geriatric assessment in oncology. J Clin Oncol 25:1936-1944, 2007.
16. Hurria A, Cleary TA, Adelman RD: Cancer in the frail elderly, in Muss HB, Hunter C, Johnson KA (eds): Treatment and Management of Cancer in the Elderly, pp 539-557. New York, Taylor & Francis, 2006.
17. Muss HB, Woolf S, Berry D, et al: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-1081, 2005.
18. Muss HB, Berry DA, Cirrincione C, et al: Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: The Cancer and Leukemia Group B experience. J Clin Oncol 25:3699-3704, 2007.
19. Guralnik JM, Simonsick EM, Ferrucci L, et al: A short physical performance battery assessing lower extremity function: Association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 49:M85-M94, 1994.
20. Abate M, Diloria A DiRenzo D, et al: Fraility in the elderly: The physical dimension. Europa Medicophysica 42:1-9, 2006.
21. Baumgartner RN, Wayne SJ, Waters DL, et al: Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res 12:1995-2004, 2004.
22. Janssen I: Influence of sarcopenia on the development of physical disability: The Cardiovascular Health Study. J Am Geriatr Soc 54:56-62, 2006.
23. Visser M, Goodpaster BH, Kritchevsky SB, et al: Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci 60:324-333, 2005.
24. Ferrucci L, Corsi A, Lauretani F, et al: The origins of age-related proinflammatory state. Blood 105:2294-2299, 2005.
25. Walston J, McBurnie MA, Newman A, et al: Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: Results from the Cardiovascular Health Study. Arch Intern Med 162:2333-2341, 2002.
26. Mitnitski AB, Song X, Rockwood K: The estimation of relative fitness and frailty in community-dwelling older adults using self-report data. J Gerontol A Biol Sci Med Sci 59:M627-M632, 2004.
27. Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104-110, 1994.
28. Satariano WA: Aging, comorbidity, and breast cancer survival: An epidemiologic view. Adv Exp Med Biol 330:1-11, 1993.
29. Bergman L, Dekker G, van Leeuwen FE, et al: The effect of age on treatment choice and survival in elderly breast cancer patients. Cancer 67:2227-2234, 1991.
30. Maas HA, Janssen-Heijnen ML, Olde Rikkert MG, et al: Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer 43:2161-2169, 2007.
31. Inouye SK, Studenski S, Tinetti ME, et al: Geriatric syndromes: Clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc 55:780-791, 2007.
32. Hurria A, Lachs MS, Cohen HJ, et al: Geriatric assessment for oncologists: Rationale and future directions. Crit Rev Oncol Hematol 59:211-217, 2006.
33. Karnofsky DA: Determining the extent of the cancer and clinical planning for cure. Cancer 22:730-734, 1968.
34. Walston J, Hadley EC, Ferrucci L, et al: Research agenda for frailty in older adults: Toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc 54:991-1001, 2006.
35. Balducci L: The geriatric cancer patient: Equal benefit from equal treatment. Cancer Control 8:1-25, 2001.
36. Monfardini S, Ferrucci L, Fratino L, et al: Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 77:395-401, 1996.
37. Repetto L, Fratino L, Audisio RA, et al: Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol 20:494-502, 2002.
38. Balducci L, Extermann M: Management of cancer in the older person: A practical approach. Oncologist 5:224-237, 2000.
39. Hurria A, Gupta S, Zauderer M, et al: Developing a cancer-specific geriatric assessment: A feasibility study. Cancer 104:1998-2005, 2005.
40. Saliba D, Elliott M, Rubenstein LZ, et al: The Vulnerable Elders Survey: A tool for identifying vulnerable older people in the community. J Am Geriatr Soc 49:1691-1699, 2001.
41. Mohile SG, Bylow K, Dale W, et al: A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 109:802-810, 2007.
42. Gill TM, Gahbauer EA, Allore HG, et al: Transitions between frailty states among community-living older persons. Arch Intern Med 166:418-423, 2006.
43. Singh MA: Exercise comes of age: rationale and recommendations for a geriatric exercise prescription. J Gerontol A Biol Sci Med Sci 57:M262-M282, 2002.
44. Leveille SG, Guralnik JM, Ferrucci L, et al: Aging successfully until death in old age: opportunities for increasing active life expectancy. Am J Epidemiol 149:654-664, 1999.
45. Landi F, Cesari M, Onder G, et al: Physical activity and mortality in frail, community-living elderly patients. J Gerontol A Biol Sci Med Sci 59:833-837, 2004.
46. Barry BK, Carson RG: The consequences of resistance training for movement control in older adults. J Gerontol A Biol Sci Med Sci 59:730-754, 2004.
47. Taaffe DR: Sarcopenia—exercise as a treatment strategy. Aust Fam Physician 35:130-134, 2006.
48. Latham NK, Bennett DA, Stretton CM, et al: Systematic review of progressive resistance strength training in older adults. J Gerontol A Biol Sci Med Sci 59:48-61, 2004.
49. Seynnes O, Fiatarone Singh MA, et al: Physiological and functional responses to low-moderate versus high-intensity progressive resistance training in frail elders. J Gerontol A Biol Sci Med Sci 59:503-509, 2004.
50. Extermann M, Meyer J, McGinnis M, et al: A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 49:69-75, 2004.
51. Arnoldi E, Dieli M, Mangia M, et al: Comprehensive geriatric assessment in elderly cancer patients: An experience in an outpatient population. Tumori 93:23-25, 2007, 2007.
52. McCorkle R, Strumpf NE, Nuamah IF, et al: A specialized home care intervention improves survival among older post-surgical cancer patients. J Am Geriatr Soc 48:1707-1713, 2000.
53. Akhtar SS, Allan SG, Rodger A, et al: A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients. Eur J Surg Oncol 17:30-35, 1991.
54. Smith I, Dowsett M, on behalf of the IMPACT Trialists: Comparison of anastrozole versus tamoxifen alone and in combination as neoadjuvant treatment of ER+ operable breast cancer in postmenopausal women: The IMPACT Trial. Presented at the Annual San Antonio Breast Cancer Symposium; San Antonio Tex; 2004.
55. Smith IE, Dowsett M: Aromatase inhibitors in breast cancer. N Engl J Med 348:2431-2442, 2003.
56. Smith IE, Dowsett M, Ebbs SR, et al: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108-5116, 2005.
57. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor- positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001.
58. Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005.
59. Witherby SM, Muss HB: Special issues related to breast cancer adjuvant therapy in older women. Breast 14:600-611, 2005.
60. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002.
61. Hutchins LF, Unger JM, Crowley JJ, et al: Underrepresentation of patients 65 years of age or older in cancer- treatment trials. N Engl J Med 341:2061-2067, 1999.
62. Sateren WB, Trimble EL, Abrams J, et al: How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 20:2109-2117, 2002.
63. Muss HB, Woolf S, Berry D, et al: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-1081, 2005.
64. Christman K, Muss HB, Case LD, et al: Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience JAMA 268:57-62, 1992.
65. Katz S, Ford AB, Moskowitz RW, et al: Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA 185:914-919, 1963.
66. Lawton MP, Brody EM: Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 9:179-186, 1969.